Essex Ophthalmology Services Limited 05866293 false 2023-08-31 2024-08-30 2024-08-30 The principal activity of the company is Ophtalmology Services Digita Accounts Production Advanced 6.30.9574.0 true false true 05866293 2023-08-31 2024-08-30 05866293 2024-08-30 05866293 bus:OrdinaryShareClass1 2024-08-30 05866293 core:CurrentFinancialInstruments 2024-08-30 05866293 core:CurrentFinancialInstruments core:WithinOneYear 2024-08-30 05866293 core:CostValuation 2024-08-30 05866293 core:DisposalsDecreaseInInvestments 2024-08-30 05866293 core:FurnitureFittingsToolsEquipment 2024-08-30 05866293 core:OtherPropertyPlantEquipment 2024-08-30 05866293 bus:SmallEntities 2023-08-31 2024-08-30 05866293 bus:AuditExemptWithAccountantsReport 2023-08-31 2024-08-30 05866293 bus:FilletedAccounts 2023-08-31 2024-08-30 05866293 bus:SmallCompaniesRegimeForAccounts 2023-08-31 2024-08-30 05866293 bus:RegisteredOffice 2023-08-31 2024-08-30 05866293 bus:CompanySecretaryDirector1 2023-08-31 2024-08-30 05866293 bus:OrdinaryShareClass1 2023-08-31 2024-08-30 05866293 bus:PrivateLimitedCompanyLtd 2023-08-31 2024-08-30 05866293 core:FurnitureFittings 2023-08-31 2024-08-30 05866293 core:FurnitureFittingsToolsEquipment 2023-08-31 2024-08-30 05866293 core:OtherPropertyPlantEquipment 2023-08-31 2024-08-30 05866293 core:PlantMachinery 2023-08-31 2024-08-30 05866293 countries:AllCountries 2023-08-31 2024-08-30 05866293 2023-08-30 05866293 core:CostValuation 2023-08-30 05866293 core:FurnitureFittingsToolsEquipment 2023-08-30 05866293 core:OtherPropertyPlantEquipment 2023-08-30 05866293 2022-08-31 2023-08-30 05866293 2023-08-30 05866293 bus:OrdinaryShareClass1 2023-08-30 05866293 core:CurrentFinancialInstruments 2023-08-30 05866293 core:CurrentFinancialInstruments core:WithinOneYear 2023-08-30 05866293 core:FurnitureFittingsToolsEquipment 2023-08-30 05866293 core:OtherPropertyPlantEquipment 2023-08-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 05866293

Essex Ophthalmology Services Limited

trading as Essex Vision

Unaudited Filleted Financial Statements

for the Year Ended 30 August 2024

 

Essex Ophthalmology Services Limited

trading as Essex Vision

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 10

 

Essex Ophthalmology Services Limited

trading as Essex Vision

Company Information

Director

Dr Jagmohan Singh Chawla

Company secretary

Dr Jagmohan Singh Chawla

Registered office

16 Mount Pleasant Avenue
Hutton
Brentwood
Essex
CM13 1PW

Accountants

McGinty Demack
Chartered Certified Accountants
Vermont House
Bradley Lane
Standish
Lancashire
WN6 0XF

 

Essex Ophthalmology Services Limited

trading as Essex Vision

(Registration number: 05866293)
Balance Sheet as at 30 August 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

-

14,889

Investments

5

-

90

 

-

14,979

Current assets

 

Debtors

6

54,714

12,351

Cash at bank and in hand

 

-

847

 

54,714

13,198

Creditors: Amounts falling due within one year

7

-

(2,234)

Net current assets

 

54,714

10,964

Net assets

 

54,714

25,943

Capital and reserves

 

Called up share capital

8

57,143

57,143

Share premium reserve

(2,429)

(2,429)

Retained earnings

-

(28,771)

Shareholders' funds

 

54,714

25,943

For the financial year ending 30 August 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

 

Essex Ophthalmology Services Limited

trading as Essex Vision

(Registration number: 05866293)
Balance Sheet as at 30 August 2024

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 11 September 2024
 

.........................................
Dr Jagmohan Singh Chawla
Company secretary and director

 

Essex Ophthalmology Services Limited

trading as Essex Vision

Notes to the Unaudited Financial Statements for the Year Ended 30 August 2024

1

General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
16 Mount Pleasant Avenue
Hutton
Brentwood
Essex
CM13 1PW

These financial statements were authorised for issue by the director on 11 September 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

 

Essex Ophthalmology Services Limited

trading as Essex Vision

Notes to the Unaudited Financial Statements for the Year Ended 30 August 2024

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Furniture and fittings

20% Reducing balance

Plant and machinery

25% Reducing balance

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

 

Essex Ophthalmology Services Limited

trading as Essex Vision

Notes to the Unaudited Financial Statements for the Year Ended 30 August 2024

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.


Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

 

Essex Ophthalmology Services Limited

trading as Essex Vision

Notes to the Unaudited Financial Statements for the Year Ended 30 August 2024

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2023 - 1).

 

Essex Ophthalmology Services Limited

trading as Essex Vision

Notes to the Unaudited Financial Statements for the Year Ended 30 August 2024

4

Tangible assets

Furniture, fittings and equipment
 £

Other tangible assets
£

Total
£

Cost or valuation

At 31 August 2023

237

169,751

169,988

Disposals

(237)

(169,751)

(169,988)

At 30 August 2024

-

-

-

Depreciation

At 31 August 2023

231

154,868

155,099

Eliminated on disposal

(231)

(154,868)

(155,099)

At 30 August 2024

-

-

-

Carrying amount

At 30 August 2024

-

-

-

At 30 August 2023

6

14,883

14,889

5

Investments

2024
£

2023
£

Investments in subsidiaries

-

90

 

Essex Ophthalmology Services Limited

trading as Essex Vision

Notes to the Unaudited Financial Statements for the Year Ended 30 August 2024

Subsidiaries

£

Cost or valuation

At 31 August 2023

90

Disposals

(90)

At 30 August 2024

-

Provision

Carrying amount

At 30 August 2024

-

At 30 August 2023

90

6

Debtors

Current

2024
£

2023
£

Other debtors

54,714

12,351

 

54,714

12,351

 

Essex Ophthalmology Services Limited

trading as Essex Vision

Notes to the Unaudited Financial Statements for the Year Ended 30 August 2024

7

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Due within one year

Trade creditors

-

498

Accruals and deferred income

-

1,650

Other creditors

-

86

-

2,234

8

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

Ordinary of £1 each

65,714

65,714

65,714

65,714